Overall, the incidence of CALR mutations in wild-type JAK2 and MPL patients was of 44% (15/34) in ET and of 14% (3/21) in persistent thrombocytosis suggestive of MPN. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.